Lupus & antiphospholipid syndrome
Real-world immune response to SARS-CoV-2 vaccination in Thai patients with systemic lupus erythematosus: a cross-sectional observational study
Authors' conclusion
Thai patients with SLE demonstrated an immune response comparable to that of healthy controls. A stronger immune response was observed in patients with SLE who received viral vector and mRNA vaccines, compared with those who received inactivated vaccines.
Study context
- Population
- Adult Thai patients with SLE and healthy controls after two SARS-CoV-2 vaccine doses under the Thai national immunisation programme
- Participants
- 92 vs 41
- Exposure
- SLE vs healthy controls
- SLEn = 92
- Controlsn = 41reference
- Outcome
- SARS-CoV-2 spike protein IgG level (electro-chemiluminescence immunoassay)
- Follow-up
- After the second dose
Methodological detailscase-control, age-matched and sex-matched healthy controls
- Case-control
- Age-matched and sex-matched healthy controls
Main finding
As reported in the abstract
SARS-CoV-2 spike protein IgG
P = 0.41
Observational data: associations, not effects.
Further findings
IgG by vaccine type in SLE
- Messenger RNA (mRNA) and viral vector vaccines yielded higher antibody levels than inactivated vaccines in patients with SLE
Factors associated with lower IgG in SLE
- Active LN and moderate-to-high dose GC use appeared associated with lower IgG, not statistically significant
Original publication
Real-world immune response to SARS-CoV-2 vaccination in Thai patients with systemic lupus erythematosus: a cross-sectional observational study. Lupus Sci Med. Published 10 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →